Quarterly report pursuant to Section 13 or 15(d)

GOODWILL AND OTHER INTANGIBLE ASSETS

v3.23.1
GOODWILL AND OTHER INTANGIBLE ASSETS
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS

6. GOODWILL AND OTHER INTANGIBLE ASSETS

 

The net carrying value of the identifiable intangible assets from all acquisitions within continuing operations as of March 31, 2023 and December 31, 2022 are as follows:

   

       

As of March 31,

2023

    

As of

December 31,

2022

  
    Life   Carrying     Carrying  
    (Years)   Amount     Amount  
                 
Asuragen acquisition:                    
Thyroid   9   $ 8,519     $ 8,519  
RedPath acquisition:                    
Pancreas test   7     16,141       16,141  
Barrett’s test   9     6,682       6,682  
                     
CLIA Lab   2.3     609       609  
                     
Total       $ 31,951     $ 31,951  
                     
Accumulated Amortization         (31,407 )     (31,090 )
                     
Net Carrying Value       $ 544     $ 861  

 

Amortization expense from continuing operations was approximately $0.3 million for both the three-month periods ended March 31, 2023 and 2022, respectively. The remaining amortization expense of $0.5 million will be amortized in 2023.